<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Options, No Certainty for a Versatile Virus IacobSimona12IacobDiana Gabriela13*[], 1Infectious" exact="Diseases" post="Department, Carol Davila University of Medicine and PharmacyBucharestRomania[], 2Infectious"/>
 <result pre="Diseases Department, Carol Davila University of Medicine and PharmacyBucharestRomania[], 2Infectious" exact="Diseases" post="Department, National Institute of Infectious Diseases â€œProf dr. Matei"/>
 <result pre="of Medicine and PharmacyBucharestRomania[], 2Infectious Diseases Department, National Institute of" exact="Infectious" post="Diseases â€œProf dr. Matei Balsâ€�BucharestRomania[], 3Infectious Diseases Department, Bucharest"/>
 <result pre="Medicine and PharmacyBucharestRomania[], 2Infectious Diseases Department, National Institute of Infectious" exact="Diseases" post="â€œProf dr. Matei Balsâ€�BucharestRomania[], 3Infectious Diseases Department, Bucharest Emergency"/>
 <result pre="National Institute of Infectious Diseases â€œProf dr. Matei Balsâ€�BucharestRomania[], 3Infectious" exact="Diseases" post="Department, Bucharest Emergency University HospitalBucharestRomania Edited by: Brian Godman,"/>
 <result pre="provoked a still ongoing and dangerous pandemic known as coronavirus" exact="disease" post="2019 (COVID-19). The SARS-CoV-2 infection has triggered an impressive"/>
 <result pre="dangerous pandemic known as coronavirus disease 2019 (COVID-19). The SARS-CoV-2" exact="infection" post="has triggered an impressive amount of clinical and experimental"/>
 <result pre="a high interspecies adaptability. CoVs possess low pathogenicity associated with" exact="respiratory" post="and enteric diseases usually of mild or medium severity."/>
 <result pre="species of CoVs have been responsible for important and severe" exact="respiratory" post="outbreaks in humans, namely the severe acute respiratory syndrome"/>
 <result pre="important and severe respiratory outbreaks in humans, namely the severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) which lead to the 2002â€&quot;2003"/>
 <result pre="and severe respiratory outbreaks in humans, namely the severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) which lead to the 2002â€&quot;2003 outbreak,"/>
 <result pre="severe respiratory outbreaks in humans, namely the severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) which lead to the 2002â€&quot;2003 outbreak, the"/>
 <result pre="(SARS-CoV) which lead to the 2002â€&quot;2003 outbreak, the Midde East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) in 2012 and the severe acute"/>
 <result pre="which lead to the 2002â€&quot;2003 outbreak, the Midde East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) in 2012 and the severe acute respiratory"/>
 <result pre="East respiratory syndrome coronavirus (MERS-CoV) in 2012 and the severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) associated with the ongoing"/>
 <result pre="respiratory syndrome coronavirus (MERS-CoV) in 2012 and the severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) associated with the ongoing pandemic"/>
 <result pre="syndrome coronavirus (MERS-CoV) in 2012 and the severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) associated with the ongoing pandemic also"/>
 <result pre="associated with the ongoing pandemic also referred to as CoV" exact="disease" post="2019 (COVID-19) (Huang et al., 2020). The COVID-19 outbreak"/>
 <result pre="molecules was proposed for the SARS-CoV-2 treatment in a very" exact="short" post="period of time and the list of molecules is"/>
 <result pre="of time and the list of molecules is still increasing." exact="Multiple" post="investigational drugs with potential antiviral activity, have been administered"/>
 <result pre="It entails 16 non-structural proteins (Nsp) which are essential for" exact="viral" post="replication and 4 other structural proteins namely the spike,"/>
 <result pre="conserved among coronaviruses such as the Nsp12-RNA-dependent-RNA-polymerase (RdRp) involved in" exact="viral" post="replication, while others such as CoV-2 Spike (S)-protein, the"/>
 <result pre="CoV-2 Spike (S)-protein, the main SARS-CoV-2 antigenic structure, express a" exact="limited" post="genetic variability. Cell invasion includes the viral entry steps"/>
 <result pre="structure, express a limited genetic variability. Cell invasion includes the" exact="viral" post="entry steps (receptor recognition, endocytosis and viral- membrane fusion)"/>
 <result pre="The host immune response is initiated as soon as the" exact="type I" post="interferon (IFN-I) response is triggered by intracellular genomic RNA."/>
 <result pre="catalysed by thr RNA-dependent RNA polymerase (RdRP) in the Replication/Transcription" exact="Complex" post="(RTC) (6); translation of viral proteins (7); assembly of"/>
 <result pre="polymerase (RdRP) in the Replication/Transcription Complex (RTC) (6); translation of" exact="viral" post="proteins (7); assembly of viral proteins and RNA into"/>
 <result pre="Complex (RTC) (6); translation of viral proteins (7); assembly of" exact="viral" post="proteins and RNA into a mature virion in the"/>
 <result pre="; the virion is released by exocytosis (9). Recognition of" exact="viral" post="RNA by endosomal RIG-I-like receptors (RLRs) and Toll-like receptors"/>
 <result pre="receptors (RLRs) and Toll-like receptors (TLRs) allows the activation of" exact="type I" post="interferon (IFNs) response, that up-regulates the expression of interferon-stimulated"/>
 <result pre="autophagy and RNA transcription (remdesivir); inhibition of 2Clpro and PLpro" exact="viral" post="proteases involved in polyprotein fragmentation (protease inhibitors namely lopinavir,"/>
 <result pre="as a Therapeutic Target The CoV-2 S protein is a" exact="type I" post="transmembrane protein. It contains two ectodomains: a receptor-binding subunit"/>
 <result pre="two ectodomains: a receptor-binding subunit (RBD) S1 which ensures the" exact="viral" post="biding to angiotensin-converting enzyme 2 (ACE2) receptor and a"/>
 <result pre="the downregulation of ACE2, an ubiquitous receptor preferentially expressed in" exact="epithelial" post="or endothelial cells (Harmer et al., 2002; Kuba et"/>
 <result pre="the equilibrium of the renin angiotensin system and protects the" exact="vascular" post="endothelia of the vital tissues such as brain, heart,"/>
 <result pre="for SARS-CoV-2. ACE2 mRNA, has a higher expression in the" exact="respiratory" post="epithelia, mostly in the nasal and alveolar epithelial cells"/>
 <result pre="in the respiratory epithelia, mostly in the nasal and alveolar" exact="epithelial" post="cells but also in the epithelial cells of the"/>
 <result pre="the nasal and alveolar epithelial cells but also in the" exact="epithelial" post="cells of the salivary gland, intestinal and renal epithelia"/>
 <result pre="epithelial cells but also in the epithelial cells of the" exact="salivary gland," post="intestinal and renal epithelia or cardiac cells (Harmer et"/>
 <result pre="et al., 2020), the prognosis of patients with cardiac or" exact="pulmonary" post="disease, diabetes or obesity appears to be worse (Fang"/>
 <result pre="2020), the prognosis of patients with cardiac or pulmonary disease," exact="diabetes" post="or obesity appears to be worse (Fang et al.,"/>
 <result pre="prognosis of patients with cardiac or pulmonary disease, diabetes or" exact="obesity" post="appears to be worse (Fang et al., 2020; Shi"/>
 <result pre="solutions have been proposed to address the interaction between the" exact="viral" post="proteins and ACE2, such as a recombinant soluble form"/>
 <result pre="entry and the fusion between the endosomal membrane and the" exact="viral" post="S2 sequence (Hoffmann et al., 2020b). Consequently, the inhibition"/>
 <result pre="potential therapeutic role as has been already shown in other" exact="viral" post="respiratory syndromes and experimental models (Kawase et al., 2012;"/>
 <result pre="therapeutic role as has been already shown in other viral" exact="respiratory" post="syndromes and experimental models (Kawase et al., 2012; Yamamoto"/>
 <result pre="al., 2020b). The endocytic pathway represents a key mechanism behind" exact="viral" post="entry. Multiple studies have currently approached the antiviral role"/>
 <result pre="The endocytic pathway represents a key mechanism behind viral entry." exact="Multiple" post="studies have currently approached the antiviral role of endosomal-tropic"/>
 <result pre="the autophagy machinery is involved in the delivery of the" exact="viral" post="genome to the host cell. The autophagy is initiated"/>
 <result pre="in COVID-19. SARS-CoV-2 Post Entry Steps and Therapeutic Targets The" exact="viral" post="invasion of the target cells implies genomic RNA translation"/>
 <result pre="the synthesis of polyproteins which are further cleaved by two" exact="viral" post="proteases, namely 3C-like protease (3CLpro) and Papain Like protease"/>
 <result pre="block these proteases but showed a debatable efficiency (RECOVERY trial)." exact="Viral" post="RNA synthesis involves two stages: genome replication and subgenomic"/>
 <result pre="by various experimental molecules (favipiravir). The final stages of the" exact="viral" post="cycle cover the viral translation of the structural proteins,"/>
 <result pre="(favipiravir). The final stages of the viral cycle cover the" exact="viral" post="translation of the structural proteins, the assembly of all"/>
 <result pre="viral translation of the structural proteins, the assembly of all" exact="viral" post="components into the endoplasmic reticulum, the recreation of the"/>
 <result pre="if targeted by specific drugs. Host Immune Response to SARS-CoV-2" exact="Infection" post="and Therapeutic Targets SARS-CoV-2 triggers the innate immune response"/>
 <result pre="innate immune response immediately after the endosomal receptors recognize the" exact="viral" post="RNA. Consequently, Toll-like receptors 7/8 and RIG-I-like receptors RIG-I/MDA-5"/>
 <result pre="and RIG-I-like receptors RIG-I/MDA-5 activate transcription factors and trigger a" exact="type I" post="IFN response. In turn, the IFN-I response stimulate infected"/>
 <result pre="stimulate infected cells to control the early stage of the" exact="viral infection" post="through the release of proinflammatory cytokines and Th1 immune"/>
 <result pre="infected cells to control the early stage of the viral" exact="infection" post="through the release of proinflammatory cytokines and Th1 immune"/>
 <result pre="imbalance of the innate immune response can potentially trigger an" exact="uncontrolled" post="release of pro-inflammatory cytokines which accompanies the acute respiratory"/>
 <result pre="trigger an uncontrolled release of pro-inflammatory cytokines which accompanies the" exact="acute" post="respiratory distress syndrome (ARDS) or other lethal organ failures"/>
 <result pre="an uncontrolled release of pro-inflammatory cytokines which accompanies the acute" exact="respiratory" post="distress syndrome (ARDS) or other lethal organ failures (Chen"/>
 <result pre="release of pro-inflammatory cytokines which accompanies the acute respiratory distress" exact="syndrome" post="(ARDS) or other lethal organ failures (Chen et al.,"/>
 <result pre="the treatment of life-threatening SARS-CoV-2 infection. However, there is still," exact="limited" post="data on the sero-conversion following the SARS-CoV-2 infection as"/>
 <result pre="is still, limited data on the sero-conversion following the SARS-CoV-2" exact="infection" post="as well as on its associated side effects, such"/>
 <result pre="on its associated side effects, such as the risk of" exact="acute" post="lung injury (Liu et al., 2019). Consequently, the synthesis"/>
 <result pre="extrapolated from the research performed on either SARS-CoV or murine" exact="hepatitis" post="virus (MHV), a prototypic member of the CoV family"/>
 <result pre="2020). The available therapeutic agents target the pathogenic steps of" exact="infection" post="(viral entry or post-entry steps) as well as the"/>
 <result pre="the unbalance of the immune response (Figure 1). Drugs Targeting" exact="Viral" post="Entry Steps Receptor Neutralization Currently, there have been various"/>
 <result pre="could significantly improve the affinity and neutralizing activity and could" exact="lower" post="the risk of resistance mutation. Still, in this case,"/>
 <result pre="mAb would require an early administration so as to precede" exact="viral" post="replication, a step which would considerably limit their practical"/>
 <result pre="treatment of ARDS as an alternative to prevent both the" exact="viral" post="entry as well as the excessive inflammatory response driven"/>
 <result pre="report its preliminary conclusions in September 2020. Additionally, a recombinant" exact="bacterial" post="derived ACE2-like enzyme named B38-CAP will be evaluated in"/>
 <result pre="B38-CAP enzyme identified in Paenibacillus sp. B38 and produced through" exact="bacterial" post="engineering shares a structural similarity to mammalian ACE2 and"/>
 <result pre="the cleavage of the S protein, and the attachment and" exact="viral" post="fusion (Savarino et al., 2003; Vincent et al., 2005)."/>
 <result pre="the 15th the FDA issued a safety alert regarding the" exact="secondary" post="arrhythmias reported in various studies and on the 18th"/>
 <result pre="an anti-Janus kinase inhibitor used as an anti-inflammatory drug in" exact="rheumatoid arthritis" post="could regulate clarthrin-mediated endoctytosis and inhibit the release of"/>
 <result pre="anti-Janus kinase inhibitor used as an anti-inflammatory drug in rheumatoid" exact="arthritis" post="could regulate clarthrin-mediated endoctytosis and inhibit the release of"/>
 <result pre="phase 3 of a clinical trial on the treatment of" exact="symptomatic" post="COVID-19 in combination with either Lopinavir/Ritonavir (NCT04320277) or remdesivir"/>
 <result pre="an immunomodulator currently approved by the FDA for treatment of" exact="polycythemia vera" post="is currently studied in a Phase 3 clinical trial"/>
 <result pre="protease inhibitor approved by the FDA in the treatment of" exact="chronic" post="pancreatitis can also block the cellular entry of SARS-CoV-2"/>
 <result pre="inhibitor approved by the FDA in the treatment of chronic" exact="pancreatitis" post="can also block the cellular entry of SARS-CoV-2 by"/>
 <result pre="key enzyme of RNA viruses with a pivotal role in" exact="viral" post="replication and mutagenesis becomes a target for the design"/>
 <result pre="of a 10-day intravenous treatment in COVID-19 patients with severe" exact="pneumonia" post="(Adaptive COVID-19 Treatment Trial ACTT-NCT04280705) (Beigel et al., 2020)."/>
 <result pre="of remdesivir on a compassionate-use basis to patients with SARS-CoV-2" exact="infection" post="receiving oxygen support, has been associated with a clinical"/>
 <result pre="lacked a randomized group and did not control for the" exact="viral" post="load, aspects which have stemmed various discussions. The authors"/>
 <result pre="5 or 10 days in patients with severe COVID-19 and" exact="pneumonia" post="(NCT04292899). The partial results of these study published in"/>
 <result pre="days in patients with severe COVID-19 and pneumonia (NCT04292899). The" exact="partial" post="results of these study published in May could not"/>
 <result pre="phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19" exact="pneumonia" post="recommends the use of Remdesivir early in the course"/>
 <result pre="remdesivir in Europe, beginning with June 2020, for patients with" exact="pneumonia" post="requiring supplemental oxygen. Remdesivir is thus the second major"/>
 <result pre="this matter. Furthermore, the administration of azithromycin also poses multiple" exact="cardiovascular" post="risks (Ray et al., 2012) and the optimistic results"/>
 <result pre="COVID-19 are closely related to the host immune response. The" exact="viral" post="RNA recognition by the intracellular receptors activates IFN-I signalling"/>
 <result pre="delayed or attenuated IFN-I response has been recorded in SARS-CoV-2" exact="infections" post="complicated with systemic inflammatory response and acute respiratory distress"/>
 <result pre="IFN-I response has been recorded in SARS-CoV-2 infections complicated with" exact="systemic" post="inflammatory response and acute respiratory distress syndrome (ARDS) (Li"/>
 <result pre="recorded in SARS-CoV-2 infections complicated with systemic inflammatory response and" exact="acute" post="respiratory distress syndrome (ARDS) (Li et al., 2020; Jose"/>
 <result pre="in SARS-CoV-2 infections complicated with systemic inflammatory response and acute" exact="respiratory" post="distress syndrome (ARDS) (Li et al., 2020; Jose and"/>
 <result pre="infections complicated with systemic inflammatory response and acute respiratory distress" exact="syndrome" post="(ARDS) (Li et al., 2020; Jose and Manuel, 2020;"/>
 <result pre="genes (ISGs) triggers specific antiviral pathways which directly target the" exact="viral" post="transcriptome and proteome activity. The interaction between the ISGs"/>
 <result pre="transcriptome and proteome activity. The interaction between the ISGs and" exact="viral" post="RNA has been better explored in other viral infections"/>
 <result pre="ISGs and viral RNA has been better explored in other" exact="viral" post="infections (Goraya et al., 2020) but has been less"/>
 <result pre="and viral RNA has been better explored in other viral" exact="infections" post="(Goraya et al., 2020) but has been less documented"/>
 <result pre="ACE2 SARS-CoV-2 receptor is an ISG found in human airway" exact="epithelial" post="cells. The authors have thus identified a surprising alternative"/>
 <result pre="plays a protective role in the initial phase of the" exact="infection" post="but later contributes to the â€œcytokine stormâ€™â€™ either directly"/>
 <result pre="induction of other cytokines, as was proved during the MERS" exact="infection" post="(Channappanavar et al., 2019). Hence, IFN therapy could play"/>
 <result pre="could play a pivotal role in COVID-19 clinical improvement and" exact="viral" post="load lasting according to a recent study (NCT04276688) (Hung"/>
 <result pre="the control group received protease inhibitors, known to display a" exact="limited" post="efficacy (Gandhi, 2020). Another notable issue on the subject"/>
 <result pre="matter, even though IFNÎ²1 displays an anti-inflammatory role on the" exact="pulmonary" post="endothelia, it does not appear to reduce the mortality"/>
 <result pre="database. Table 1 Interferon therapy in clinical evaluation in SARS-CoV-2" exact="infection" post="(July 20, 2020). Biological treatment Study identifier number, locations"/>
 <result pre="potent viruses to initiate the sepsis cascade and to induce" exact="pulmonary" post="lesions with theÂ development of ARDS (Lin et al.,"/>
 <result pre="all severe forms, correlated with the incidence of the plasma" exact="viral" post="load (Chen et al., 2020) or other endogenic factors"/>
 <result pre="et al., 2020) or other endogenic factors such as diabetes," exact="cardiovascular disease" post="or their associated treatments (Qu et al., 2014). Antiinflammatory"/>
 <result pre="al., 2020) or other endogenic factors such as diabetes, cardiovascular" exact="disease" post="or their associated treatments (Qu et al., 2014). Antiinflammatory"/>
 <result pre="drugs acting in monotherapy or in combination could potentially alleviate" exact="pulmonary" post="inflammation and could be indicated in severe respiratory forms"/>
 <result pre="potentially alleviate pulmonary inflammation and could be indicated in severe" exact="respiratory" post="forms such as ARDS. Such examples include tocilizumab, a"/>
 <result pre="anti IL-6 receptor mAb commonly used in the treatment of" exact="rheumatoid arthritis" post="and also approved in the treatment of cytokine release"/>
 <result pre="IL-6 receptor mAb commonly used in the treatment of rheumatoid" exact="arthritis" post="and also approved in the treatment of cytokine release"/>
 <result pre="has already been approved in COVID-19 critical patients with severe" exact="respiratory" post="failure. Other mAb which could mediate the release of"/>
 <result pre="with an immunomodulatory role for which it is used in" exact="autoimmune diseases." post="Although GM-CSF plays a central role to coordinate the"/>
 <result pre="using immunomodulatory drugs with scarce data on their efficiency in" exact="viral" post="or autoimune diseases, such as thalidomide (NCT04273529, NCT04273581) or"/>
 <result pre="of COVID-19 and to adopt differential strategies between the early" exact="viral" post="invasion stage and the late stage dominated by a"/>
 <result pre="immune dysregulation and the inflammatory response that is triggered by" exact="viral" post="particles in the respiratory tract (Channappanavar and Perlman, 2017;"/>
 <result pre="inflammatory response that is triggered by viral particles in the" exact="respiratory" post="tract (Channappanavar and Perlman, 2017; Huang et al., 2020)."/>
 <result pre="et al., 2008). Currently, MSC have been successfully used for" exact="immune disorder" post="therapy and graft-versus-host disease (Aggarwal and Pittenger, 2005). Even"/>
 <result pre="have been successfully used for immune disorder therapy and graft-versus-host" exact="disease" post="(Aggarwal and Pittenger, 2005). Even though the impact of"/>
 <result pre="the intravenous administration of MSC in patients with severe COVID-19" exact="pneumonia" post="shifts the immune response from a Th1 to a"/>
 <result pre="a clinical setting, this translates to an attenuation of the" exact="respiratory" post="failure after 2â€&quot;4 days (Qu et al., 2020). The"/>
 <result pre="MSC. Table 2 Cellular therapies in clinical evaluation in SARS-Cov2" exact="infection" post="(July 20, 2020). Biological product Study identifier number, country"/>
 <result pre="(July 20, 2020). Biological product Study identifier number, country Allogeneic" exact="adult" post="MSC of expanded adipose tissue NCT04366323, Spain Allogenic and"/>
 <result pre="(HB-adMSCs) NCT04349631, SUA Allogenic pooled olfactory mucosa-derived MSC NCT04382547, Belarus" exact="Placental" post="MSC exosomes ISRCTN33578935, Germany Umbilical cord-derived MSC NCT04333368, France"/>
 <result pre="olfactory mucosa-derived MSC NCT04382547, Belarus Placental MSC exosomes ISRCTN33578935, Germany" exact="Umbilical" post="cord-derived MSC NCT04333368, France Umbilical cord-derived MSC NCT04366271, Spain"/>
 <result pre="Placental MSC exosomes ISRCTN33578935, Germany Umbilical cord-derived MSC NCT04333368, France" exact="Umbilical" post="cord-derived MSC NCT04366271, Spain Umbilical cord-derived MSC (hucMSCs) ChiCTR2000030300,"/>
 <result pre="Umbilical cord-derived MSC NCT04333368, France Umbilical cord-derived MSC NCT04366271, Spain" exact="Umbilical" post="cord-derived MSC (hucMSCs) ChiCTR2000030300, China Umbilical cord-derived MSC (UC-MSC)"/>
 <result pre="cord-derived MSC NCT04366271, Spain Umbilical cord-derived MSC (hucMSCs) ChiCTR2000030300, China" exact="Umbilical" post="cord-derived MSC (UC-MSC) NCT04355728, SUA Human umbilical cord-derived MSC"/>
 <result pre="MSC ChiCTR2000030116, ChinaÂ Human umbilical cord-derived MSC (UC-MSCs) NCT04269525, China" exact="Umbilical" post="cord blood mononuclear cells ChiCTR2000029572, ChinaÂ Human embryonic-stem cells"/>
 <result pre="SUA MSC in combination with ruxolitinib ChiCTR2000029580, ChinaÂ Allogeneic human" exact="dental" post="pulp derived-stem cells NCT04336254, China Natural Killer Cells NCT04280224,"/>
 <result pre="NCT04365101, SUA M1 (type I macrophage) inhibition therapy ChiCTR2000029431, China" exact="Mesenchymal" post="stem cells, MSC. Resources: U.S. National Library of Medicine"/>
 <result pre="humoral response (Wu F. et al., 2020) or to the" exact="absence of" post="certain information regarding the effective dosing size or the"/>
 <result pre="COVID-19 study groups only, so that presently there is only" exact="limited" post="data on this therapy (Bloch et al., 2020). Side"/>
 <result pre="China)/December, 2020 Gam-COVID-Vac (Gamaleya Research Institute, Health Ministry of the" exact="Russian" post="Federation); adenoviral-based vaccine/18 to 60 years NCT04436471 (ph 1,"/>
 <result pre="Russian Federation); adenoviral-based vaccine/18 to 60 years NCT04436471 (ph 1," exact="Russian" post="Federation/August, 2020 Gam-COVID-Vac Lyo (Gamaleya Research Institute, Health Ministry"/>
 <result pre="2020 Gam-COVID-Vac Lyo (Gamaleya Research Institute, Health Ministry of the" exact="Russian" post="Federation/Accellena Research); lyophilizate adenoviral-based vaccine/18 to 60 years NCT04437875"/>
 <result pre="Research); lyophilizate adenoviral-based vaccine/18 to 60 years NCT04437875 (Phase 1-2," exact="Russian" post="Federation/August, 2020 LV-SMENP-DC vaccine (Shenzhen Geno-Immune Medical Institute); lentiviral"/>
 <result pre="vaccine (Shenzhen Geno-Immune Medical Institute); lentiviral vector system (NHP/TYF) expressing" exact="viral" post="proteins and immune modulatory genes to modify dendritic cells"/>
 <result pre="2023 SARS-CoV-2 aAPC Vaccine (Shenzhen Geno-Immune Medical Institute); NHP/TYF expressing" exact="viral" post="proteins and modified artificial antigen-presenting cell (APC) to reactivate"/>
 <result pre="SUA)/November, 2021 mRNA-1273 (mRNA-1273 + Placebo) (Moderna TX Inc, Biomedical" exact="Advanced" post="Research and Development Authority); two dose levels of mRNA-1273"/>
 <result pre="Hoffmann et al., 2020b)* multiple targets: TMPRSS2, endosomal fusion NCT04321096" exact="Viral" post="synthesis Protease inhibitors: lopinavir/darunavir/ritonavir(3CLpro, PLpro) RECOVERY trial, NCT04251871, NCT04255017,"/>
 <result pre="Wu et al., 2020a; Wang Y. et al., 2020)*multiple targets:" exact="viral" post="autophagy, mTORC1, Nsp12-RdRp, replicase/transcription complex â€&quot;RTC Trial ACTT-NCT04280705 si"/>
 <result pre="Y. et al., 2020) (anti GM-CSF mAb) BREATH clinical trial" exact="Inflammatory" post="response Corticosteroids (Horby et al., 2020; Wu et al.,"/>
 <result pre="Wu et al., 2020b). UK RECOVERY trial NCT04381936 Immuno-modulatoy activity" exact="Mesenchymal" post="stem cells (Shi et al., 2018; Leng et al.,"/>
 <result pre="has met major obstacles since the beginning such as the" exact="absence of" post="clear data on the immune response elicited by SARS-CoV-2"/>
 <result pre="is simple but there could be obstacles regarding vaccine delivery." exact="Multiple" post="transport systems have been tested such as lipid nanoparticles,"/>
 <result pre="NVX-CoV2373 by Novavax). Non-Specific Vaccines. BCG, the vaccine against Mycobacterium" exact="tuberculosis" post="is the non-specific vaccine which has received most attention"/>
 <result pre="non-specific vaccine which has received most attention in the SARS-CoV-2" exact="infection" post="due to its ability to boost the immunity against"/>
 <result pre="antigens delivered through a vector already used in ophthalmology (adeno-associated" exact="viral" post="vectors/AAV), which differs from the human adenoviral vector. The"/>
 <result pre="that the immune response to the vaccine can be variable," exact="short" post="or incomplete and that the vulnerable groups do not"/>
 <result pre="immune response to the vaccine can be variable, short or" exact="incomplete" post="and that the vulnerable groups do not always respond"/>
 <result pre="to offer short-term solutions, especially for patients with a severe" exact="disease" post="(Tu et al., 2020). As a result, it has"/>
 <result pre="which could be beneficial in a certain stage of the" exact="disease" post="could be devastating in another. Hence, the best treatment"/>
 <result pre="treatment option appears to be a molecule which would restrict" exact="viral" post="entry and to impede an unpredictable immune response. On"/>
 <result pre="of a rapid treatment, current therapeutic approaches represent a stepping" exact="stone" post="for the handling of future epidemics. The SARS-CoV-2 infection"/>
 <result pre="stepping stone for the handling of future epidemics. The SARS-CoV-2" exact="infection" post="proved once again that viruses leave a very short"/>
 <result pre="SARS-CoV-2 infection proved once again that viruses leave a very" exact="short" post="window of opportunity, far too short for adequate antiviral"/>
 <result pre="viruses leave a very short window of opportunity, far too" exact="short" post="for adequate antiviral options. This unfortunate prospect is now"/>
 <result pre="brutal warning that our current therapeutic agents are insufficient against" exact="infectious" post="agents and that non-etiologic medications could potentially play an"/>
 <result pre="The authors declare that the research was conducted in the" exact="absence of" post="any commercial or financial relationships that could be construed"/>
 <result pre="10.1182/blood-2004-04-155915494428 AgostiniM. L.AndresE. L.SimsA. C.GrahamR. L.SheahanT. P.LuX.et al. (2018). Coronavirus" exact="Susceptibility to" post="the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral"/>
 <result pre="Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the" exact="Viral" post="Polymerase and the Proofreading Exoribonuclease. MBio9 (2), e00221-18. 10.1128/mBio.00221-1829511076"/>
 <result pre="10.1128/mBio.00221-1829511076 AgrawalA. S.TaoX.AlgaissiA.GarronT.NarayananK.PengB.-H.et al. (2016). Immunization with inactivated Middle East" exact="Respiratory" post="Syndrome coronavirus vaccine leads to lung immunopathology on challenge"/>
 <result pre="AgrawalA. S.TaoX.AlgaissiA.GarronT.NarayananK.PengB.-H.et al. (2016). Immunization with inactivated Middle East Respiratory" exact="Syndrome" post="coronavirus vaccine leads to lung immunopathology on challenge with"/>
 <result pre="cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-basedÂ" exact="cardiovascular" post="therapies.1. Intern. Emerg. Med.1 19, 1â€&quot;8. 10.1007/s11739-020-02364-6 AlsaadiE. A."/>
 <result pre="N. Engl. J. Med.4 (2), 93â€&quot;107. 10.4049/immunohorizons.2000002 BellinganG.JaconoF.Bannard-SmithJ.BrealeyD.MeyerN.ThickettD.et al. (2019)." exact="Primary" post="Analysis of a Phase 1/2 Study to Assess MultiStemÂ®"/>
 <result pre="Phase 1/2 Study to Assess MultiStemÂ® Cell Therapy, a Regenerative" exact="Advanced" post="Therapy Medicinal Product (ATMP), in Acute Respiratory Distress Syndrome"/>
 <result pre="Cell Therapy, a Regenerative Advanced Therapy Medicinal Product (ATMP), in" exact="Acute" post="Respiratory Distress Syndrome (MUST-ARDS). In: B14 LATE BREAKING CLINICAL"/>
 <result pre="Therapy, a Regenerative Advanced Therapy Medicinal Product (ATMP), in Acute" exact="Respiratory" post="Distress Syndrome (MUST-ARDS). In: B14 LATE BREAKING CLINICAL TRIALS"/>
 <result pre="Regenerative Advanced Therapy Medicinal Product (ATMP), in Acute Respiratory Distress" exact="Syndrome" post="(MUST-ARDS). In: B14 LATE BREAKING CLINICAL TRIALS (American Thoracic"/>
 <result pre="Distress Syndrome (MUST-ARDS). In: B14 LATE BREAKING CLINICAL TRIALS (American" exact="Thoracic" post="Society), A7353â€&quot;A7353. 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A7353 BenderA. T.TzvetkovE.PereiraA.WuY.KasarS.PrzetakM. M.et al. (2020). TLR7"/>
 <result pre="Invest.130 (6), 2757â€&quot;2765. 10.1172/JCI13874532254064 BollesM.DemingD.LongK.AgnihothramS.WhitmoreA.FerrisM.et al. (2011). A double-inactivated severe" exact="acute" post="respiratory syndrome coronavirus vaccine provides incomplete protection in mice"/>
 <result pre="(6), 2757â€&quot;2765. 10.1172/JCI13874532254064 BollesM.DemingD.LongK.AgnihothramS.WhitmoreA.FerrisM.et al. (2011). A double-inactivated severe acute" exact="respiratory" post="syndrome coronavirus vaccine provides incomplete protection in mice and"/>
 <result pre="2757â€&quot;2765. 10.1172/JCI13874532254064 BollesM.DemingD.LongK.AgnihothramS.WhitmoreA.FerrisM.et al. (2011). A double-inactivated severe acute respiratory" exact="syndrome" post="coronavirus vaccine provides incomplete protection in mice and induces"/>
 <result pre="(2011). A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides" exact="incomplete" post="protection in mice and induces increased eosinophilic proinflammatory pulmonary"/>
 <result pre="coronavirus vaccine provides incomplete protection in mice and induces increased" exact="eosinophilic" post="proinflammatory pulmonary response upon challenge. J. Virol.85 (23), 12201â€&quot;12215."/>
 <result pre="provides incomplete protection in mice and induces increased eosinophilic proinflammatory" exact="pulmonary" post="response upon challenge. J. Virol.85 (23), 12201â€&quot;12215. 10.1128/JVI.06048-1121937658 BorbaM."/>
 <result pre="of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized"/>
 <result pre="Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical"/>
 <result pre="Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial."/>
 <result pre="as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA"/>
 <result pre="al. (2020). A Trial of Lopinavir-Ritonavir in Adults Hospitalized with" exact="Severe" post="Covid-19. N. Engl. J. Med382 (19), 1787â€&quot;1789. 10.1056/NEJMoa200128232187464 CegolonL.PichierriJ.MastrangeloG.CinquettiS.SotgiuG.BellizziS.et"/>
 <result pre="Immunopathol.39 (5), 529â€&quot;539. 10.1007/s00281-017-0629-x28466096 ChannappanavarR.FehrA. R.VijayR.MackM.ZhaoJ.MeyerholzD. K.et al. (2016). Dysregulated" exact="Type I" post="Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in"/>
 <result pre="ChannappanavarR.FehrA. R.VijayR.MackM.ZhaoJ.MeyerholzD. K.et al. (2016). Dysregulated Type I Interferon and" exact="Inflammatory" post="Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell"/>
 <result pre="(2016). Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause" exact="Lethal" post="Pneumonia in SARS-CoV-Infected Mice. Cell Host. Microbe19 (2), 181â€&quot;193."/>
 <result pre="Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal" exact="Pneumonia" post="in SARS-CoV-Infected Mice. Cell Host. Microbe19 (2), 181â€&quot;193. 10.1016/j.chom.2016.01.00726867177"/>
 <result pre="IFN-I response timing relative to virus replication determines MERS coronavirus" exact="infection" post="outcomes. J. Clin. Invest.129 (9), 3625â€&quot;3639. 10.1172/JCI12636331355779 ChenX.ZhaoB.QuY.ChenY.XiongJ.FengY.et al."/>
 <result pre="Invest.129 (9), 3625â€&quot;3639. 10.1172/JCI12636331355779 ChenX.ZhaoB.QuY.ChenY.XiongJ.FengY.et al. (2020). Detectable serum SARS-CoV-2" exact="viral" post="load (RNAaemia) is closely associated with drastically elevated interleukin"/>
 <result pre="D.BartlettJ. H.ZakiS. R.et al. (2010). Cellular immune responses to severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice:"/>
 <result pre="H.ZakiS. R.et al. (2010). Cellular immune responses to severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+"/>
 <result pre="R.et al. (2010). Cellular immune responses to severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T"/>
 <result pre="Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV)" exact="infection" post="in senescent BALB/c mice: CD4+ T cells are important"/>
 <result pre="al. (2020). Induction of pro-inflammatory cytokines (IL-1 and IL-6) and" exact="lung inflammation" post="by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J. Biol."/>
 <result pre="al. (2002). Angiotensin-converting enzyme 2 is an essential regulator of" exact="heart" post="function. Nature417 (6891), 822â€&quot;828. 10.1038/nature0078612075344 CruzF. F.RoccoP. R. M."/>
 <result pre="822â€&quot;828. 10.1038/nature0078612075344 CruzF. F.RoccoP. R. M. (2019). Cell therapy for" exact="acute" post="respiratory distress syndrome patients: the START study. J. Thorac."/>
 <result pre="10.1038/nature0078612075344 CruzF. F.RoccoP. R. M. (2019). Cell therapy for acute" exact="respiratory" post="distress syndrome patients: the START study. J. Thorac. Dis.11"/>
 <result pre="F.RoccoP. R. M. (2019). Cell therapy for acute respiratory distress" exact="syndrome" post="patients: the START study. J. Thorac. Dis.11 (Suppl 9),"/>
 <result pre="(2020). Arbidol combined with LPV/r versus LPV/r alone against Corona" exact="Virus Disease" post="2019: A retrospective cohort study. J. Infect.81 (1), e1â€&quot;5."/>
 <result pre="Arbidol combined with LPV/r versus LPV/r alone against Corona Virus" exact="Disease" post="2019: A retrospective cohort study. J. Infect.81 (1), e1â€&quot;5."/>
 <result pre="Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike" exact="Protein" post="Are More Broadly Neutralizing. Pyrc K, editor. PloS One7"/>
 <result pre="PloS One7 (11), e50366. 10.1371/journal.pone.005036623185609 FangL.KarakiulakisG.RothM. (2020). Are patients with" exact="hypertension" post="and diabetes mellitus at increased risk for COVID-19 infection?"/>
 <result pre="(11), e50366. 10.1371/journal.pone.005036623185609 FangL.KarakiulakisG.RothM. (2020). Are patients with hypertension and" exact="diabetes mellitus" post="at increased risk for COVID-19 infection? Lancet Respir. Med.8"/>
 <result pre="and Drug Administration (CBER) (2018). Fatalities Reported to FDA Following" exact="Blood" post="Collection and Transfusion: Annual Summary for FY2018. Cent. Biol."/>
 <result pre="trial. Lancet. Â 10.1016/S0140-6736(20)31604-4 FungS.-Y.YuenK.-S.YeZ.-W.ChanC.-P.JinD.-Y. (2020). A tug-of-war between severe" exact="acute" post="respiratory syndrome coronavirus 2 and host antiviral defence: lessons"/>
 <result pre="Lancet. Â 10.1016/S0140-6736(20)31604-4 FungS.-Y.YuenK.-S.YeZ.-W.ChanC.-P.JinD.-Y. (2020). A tug-of-war between severe acute" exact="respiratory" post="syndrome coronavirus 2 and host antiviral defence: lessons from"/>
 <result pre="Â 10.1016/S0140-6736(20)31604-4 FungS.-Y.YuenK.-S.YeZ.-W.ChanC.-P.JinD.-Y. (2020). A tug-of-war between severe acute respiratory" exact="syndrome" post="coronavirus 2 and host antiviral defence: lessons from other"/>
 <result pre="(2020). Remdesivir for 5 or 10 Days in Patients with" exact="Severe" post="Covid-19. N.Â Engl. J. Med.27, NEJMoa2015301. Â 10.1056/NEJMoa2015301 GorayaM."/>
 <result pre="GreinJ.OhmagariN.ShinD.DiazG.AspergesE.CastagnaA.et al. (2020). Compassionate Use of Remdesivir for Patients with" exact="Severe" post="Covid-19. N. Engl. J. Med.382 (24), 2327â€&quot;2336. 10.1056/NEJMoa200701632275812 HammingI.TimensW.BulthuisM."/>
 <result pre="10.1016/S0014-5793(02)03640-212459472 HoffmannM.Kleine-WeberH.PÃ¶hlmannS. (2020a). A Multibasic Cleavage Site in the Spike" exact="Protein" post="of SARS-CoV-2 Is Essential for Infection of Human Lung"/>
 <result pre="Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is" exact="Essential" post="for Infection of Human Lung Cells. Mol. Cell.78 (4),"/>
 <result pre="Site in the Spike Protein of SARS-CoV-2 Is Essential for" exact="Infection" post="of Human Lung Cells. Mol. Cell.78 (4), 779â€&quot;784.e5. 10.1016/j.molcel.2020.04.02232362314"/>
 <result pre="(10238), 1695â€&quot;1704. 10.1016/S0140-6736(20)31042-4 InoueY.TanakaN.TanakaY.InoueS.MoritaK.ZhuangM.et al. (2007). Clathrin-dependent entry of severe" exact="acute" post="respiratory syndrome coronavirus into target cells expressing ACE2 with"/>
 <result pre="1695â€&quot;1704. 10.1016/S0140-6736(20)31042-4 InoueY.TanakaN.TanakaY.InoueS.MoritaK.ZhuangM.et al. (2007). Clathrin-dependent entry of severe acute" exact="respiratory" post="syndrome coronavirus into target cells expressing ACE2 with the"/>
 <result pre="10.1016/S0140-6736(20)31042-4 InoueY.TanakaN.TanakaY.InoueS.MoritaK.ZhuangM.et al. (2007). Clathrin-dependent entry of severe acute respiratory" exact="syndrome" post="coronavirus into target cells expressing ACE2 with the cytoplasmic"/>
 <result pre="10.1503/cmaj.200528 KawaseM.ShiratoK.van der HoekL.TaguchiF.MatsuyamaS. (2012). Simultaneous treatment of human bronchial" exact="epithelial" post="cells with serine and cysteine protease inhibitors prevents severe"/>
 <result pre="epithelial cells with serine and cysteine protease inhibitors prevents severe" exact="acute" post="respiratory syndrome coronavirus entry. J. Virol.86 (12), 6537â€&quot;6545. 10.1128/JVI.00094-1222496216"/>
 <result pre="cells with serine and cysteine protease inhibitors prevents severe acute" exact="respiratory" post="syndrome coronavirus entry. J. Virol.86 (12), 6537â€&quot;6545. 10.1128/JVI.00094-1222496216 KewanT.CovutF.Alâ€&quot;JaghbeerM."/>
 <result pre="with serine and cysteine protease inhibitors prevents severe acute respiratory" exact="syndrome" post="coronavirus entry. J. Virol.86 (12), 6537â€&quot;6545. 10.1128/JVI.00094-1222496216 KewanT.CovutF.Alâ€&quot;JaghbeerM. J.RoseL.GopalakrishnaK."/>
 <result pre="pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in" exact="acute" post="respiratory distress syndrome. Crit. Care21 (1), 234. 10.1186/s13054-017-1823-x28877748 KrasnodembskayaA.SongY.FangX.GuptaN.SerikovV.LeeJ.-W.et"/>
 <result pre="clinical trial of recombinant human angiotensin-converting enzyme 2 in acute" exact="respiratory" post="distress syndrome. Crit. Care21 (1), 234. 10.1186/s13054-017-1823-x28877748 KrasnodembskayaA.SongY.FangX.GuptaN.SerikovV.LeeJ.-W.et al."/>
 <result pre="study. medRxiv. 2020.04.08.20054551. 10.1101/2020.04.08.20054551 LengZ.ZhuR.HouW.FengY.YangY.HanQ.et al. (2020). Transplantation of ACE2-" exact="Mesenchymal" post="Stem Cells Improves the Outcome of Patients with COVID-19"/>
 <result pre="Aging Dis.11 (2), 216. 10.14336/AD.2020.022832257537 LiH.LiuL.ZhangD.XuJ.DaiH.TangN.et al. (2020). SARS-CoV-2 and" exact="viral" post="sepsis: observations and hypotheses. Lancet395 (10235), 1517â€&quot;1520. 10.1016/S0140-6736(20)30920-X32311318 LiG.RachmaleS.KojicicM.ShahjehanK.MalinchocM.KorD."/>
 <result pre="is not associated with improved outcomes in patients with coronavirus" exact="disease" post="2019: a retrospective study. Clin. Microbiol. Infect.26 (7), 917â€&quot;921."/>
 <result pre="LinG.-L.McGinleyJ. P.DrysdaleS. B.PollardA. J. (2018). Epidemiology and Immune Pathogenesis of" exact="Viral" post="Sepsis. Front. Immunol.9, 2147. 10.3389/fimmu.2018.0214730319615 LiuL.WeiQ.LinQ.FangJ.WangH.KwokH.et al. (2019). Antiâ€&quot;spike"/>
 <result pre="Immunol.9, 2147. 10.3389/fimmu.2018.0214730319615 LiuL.WeiQ.LinQ.FangJ.WangH.KwokH.et al. (2019). Antiâ€&quot;spike IgG causes severe" exact="acute" post="lung injury by skewing macrophage responses during acute SARS-CoV"/>
 <result pre="causes severe acute lung injury by skewing macrophage responses during" exact="acute" post="SARS-CoV infection. JCI Insight4 (4), e123158. 10.1172/jci.insight.123158 MacchiagodenaM.PagliaiM.ProcacciP. (2020)."/>
 <result pre="Inhibition of the Main Protease 3CL Pro of the Coronavirus" exact="Disease" post="19 via Structure-Based Ligand Design and Molecular Modeling. arXiv.org"/>
 <result pre="The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting" exact="viral" post="NSP15. bioRxiv.2020.03.11.987016. 10.1101/2020.03.11.987016 MeyerS.BojkovaD.CinatiJ.DammeE.V.BuyckC.LoockM.V.et al. (2020). Lack of Antiviral"/>
 <result pre="al. (2020). B38-CAP is a bacteria-derived ACE2-like enzyme that suppresses" exact="hypertension" post="and cardiac dysfunction. Nat. Commun.11 (1), 1058. 10.1038/s41467-020-14867-z32103002 MonteilV.KwonH.PradoP.HagelkrÃ¼ysA.WimmerR."/>
 <result pre="(1), 1058. 10.1038/s41467-020-14867-z32103002 MonteilV.KwonH.PradoP.HagelkrÃ¼ysA.WimmerR. A.StahlM.et al. (2020). Inhibition of SARS-CoV-2" exact="Infections" post="in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2."/>
 <result pre="of the putative SARS-CoV-2 receptor ACE2 in human hearts. Eur." exact="Heart" post="J.41 (19), 1804â€&quot;1806. 10.1093/eurheartj/ehaa31132293672 PicotS.PeyronF.DonadilleA.VuillezJ. P.BarbeG.Ambroise-ThomasP. (1993). Chloroquine-induced inhibition"/>
 <result pre="Allergy Immunol.38 (1), 1â€&quot;9. 10.12932/AP-200220-0772 QuD.LiuJ.LauC. W.HuangY. (2014). IL-6 in" exact="diabetes" post="and cardiovascular complications. Br. J. Pharmacol.171 (15), 3595â€&quot;3603. 10.1111/bph.1271324697653"/>
 <result pre="(1), 1â€&quot;9. 10.12932/AP-200220-0772 QuD.LiuJ.LauC. W.HuangY. (2014). IL-6 in diabetes and" exact="cardiovascular" post="complications. Br. J. Pharmacol.171 (15), 3595â€&quot;3603. 10.1111/bph.1271324697653 QuW.WangZ.HareJ. M.BuG.MalleaJ."/>
 <result pre="COVID -19: Systematic review and meta-analysis of human studies on" exact="acute" post="respiratory distress syndrome. Stem Cells Transl. Med.sctm.20-0146. 10.1002/sctm.20-0146 RanieriV."/>
 <result pre="-19: Systematic review and meta-analysis of human studies on acute" exact="respiratory" post="distress syndrome. Stem Cells Transl. Med.sctm.20-0146. 10.1002/sctm.20-0146 RanieriV. M.PettilÃ¤V.KarvonenM."/>
 <result pre="Days Free From Mechanical Ventilation Among Patients With Moderate to" exact="Severe" post="Acute Respiratory Distress Syndrome. JAMA323 (8), 725. 10.1001/jama.2019.22525 RayW."/>
 <result pre="Free From Mechanical Ventilation Among Patients With Moderate to Severe" exact="Acute" post="Respiratory Distress Syndrome. JAMA323 (8), 725. 10.1001/jama.2019.22525 RayW. A.MurrayK."/>
 <result pre="From Mechanical Ventilation Among Patients With Moderate to Severe Acute" exact="Respiratory" post="Distress Syndrome. JAMA323 (8), 725. 10.1001/jama.2019.22525 RayW. A.MurrayK. T.HallK.ArbogastP."/>
 <result pre="10.1056/NEJMoa200897532356628 RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.et al. (2020). Baricitinib as potential treatment for 2019-nCoV" exact="acute" post="respiratory disease. Lancet (London England)395 (10223), e30â€&quot;e31. 10.1016/S0140-6736(20)30304-4 RogersT."/>
 <result pre="RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.et al. (2020). Baricitinib as potential treatment for 2019-nCoV acute" exact="respiratory" post="disease. Lancet (London England)395 (10223), e30â€&quot;e31. 10.1016/S0140-6736(20)30304-4 RogersT. F.ZhaoF.HuangD.BeutlerN.BurnsA.HeW.et"/>
 <result pre="(2020). Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from" exact="disease" post="in a small animal model. Scienceeabc7520. 10.1126/science.abc7520 RygÃ¥rdS. L.HolstL."/>
 <result pre="a small animal model. Scienceeabc7520. 10.1126/science.abc7520 RygÃ¥rdS. L.HolstL. B.PernerA. (2018)." exact="Blood" post="Product Administration in the Critical Care and Perioperative Settings."/>
 <result pre="Perioperative Settings. Crit. Care Clin.34 (2), 299â€&quot;311. 10.1016/j.ccc.2017.12.00529482908 SallardE.LescureF.-X.YazdanpanahY.MentreF.Peiffer-SmadjaN. (2020)." exact="Type 1" post="interferons as a potential treatment against COVID-19. Antiviral Res.178,"/>
 <result pre="Res.178, 104791. 10.1016/j.antiviral.2020.10479132275914 SavarinoA.BoelaertJ. R.CassoneA.MajoriG.CaudaR. (2003). Effects of chloroquine on" exact="viral" post="infections: an old drug against todayâ€™s diseases? Lancet Infect."/>
 <result pre="D.GralinskiL.Case JBL. S.et al. (2017). Broad-spectrum Antiviral GS-5734 Inhibits Both" exact="Epidemic" post="and Zoonotic Coronaviruses. Sci. Transl. Med.9 (396), 1â€&quot;25. 10.1126/SCITRANSLMED.AAL3653"/>
 <result pre="on immune responses. Cell Death Differ.1â€&quot;4. 10.1038/s41418-020-0530-331745213 ShiY.YuX.ZhaoH.WangH.ZhaoR.ShengJ. (2020b). Host" exact="susceptibility to" post="severe COVID-19 and establishment of a host risk score:"/>
 <result pre="Wuhan. Crit. Care24 (1), 108. 10.1186/s13054-020-2833-732188484 SpaethE.KloppA.DembinskiJ.AndreeffM.MariniF. (2008). Inflammation and" exact="tumor" post="microenvironments: defining the migratory itinerary of mesenchymal stem cells."/>
 <result pre="10.1016/S1473-3099(20)30132-832113509 SuiJ.LiW.MurakamiA.TaminA.MatthewsL. J.WongS. K.et al. (2004). Potent neutralization of severe" exact="acute" post="respiratory syndrome (SARS) coronavirus by a human mAb to"/>
 <result pre="SuiJ.LiW.MurakamiA.TaminA.MatthewsL. J.WongS. K.et al. (2004). Potent neutralization of severe acute" exact="respiratory" post="syndrome (SARS) coronavirus by a human mAb to S1"/>
 <result pre="J.WongS. K.et al. (2004). Potent neutralization of severe acute respiratory" exact="syndrome" post="(SARS) coronavirus by a human mAb to S1 protein"/>
 <result pre="ToK. K.-W.TsangO. T.-Y.LeungW.-S.TamA. R.WuT.-C.LungD. C.et al. (2020). Temporal profiles of" exact="viral" post="load in posterior oropharyngeal saliva samples and serum antibody"/>
 <result pre="R.WuT.-C.LungD. C.et al. (2020). Temporal profiles of viral load in" exact="posterior" post="oropharyngeal saliva samples and serum antibody responses during infection"/>
 <result pre="in posterior oropharyngeal saliva samples and serum antibody responses during" exact="infection" post="by SARS-CoV-2: an observational cohort study. Lancet Infect. Dis.20"/>
 <result pre="L.et al. (2012). Immunization with SARS Coronavirus Vaccines Leads to" exact="Pulmonary" post="Immunopathology on Challenge with the SARS Virus. PloS One7"/>
 <result pre="al. (2005). Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spread. Virol. J.2 (1), 69. 10.1186/1743-422X-2-6916115318 VossA. (2020)."/>
 <result pre="the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long" exact="Structural" post="Studies of SARS Coronavirus. J. Virol.94 (7), e00127-20. 10.1128/JVI.00127-2031996437"/>
 <result pre="(5), 766â€&quot;788. 10.1016/j.apsb.2020.02.00832292689 WuC.ChenX.CaiY.XiaJ.ZhouX.XuS.et al. (2020b). Risk Factors Associated With" exact="Acute" post="Respiratory Distress Syndrome and Death in Patients With Coronavirus"/>
 <result pre="766â€&quot;788. 10.1016/j.apsb.2020.02.00832292689 WuC.ChenX.CaiY.XiaJ.ZhouX.XuS.et al. (2020b). Risk Factors Associated With Acute" exact="Respiratory" post="Distress Syndrome and Death in Patients With Coronavirus Disease"/>
 <result pre="WuC.ChenX.CaiY.XiaJ.ZhouX.XuS.et al. (2020b). Risk Factors Associated With Acute Respiratory Distress" exact="Syndrome" post="and Death in Patients With Coronavirus Disease 2019 Pneumonia"/>
 <result pre="Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus" exact="Disease" post="2019 Pneumonia in Wuhan, China. JAMA Intern. Med.180 (7),"/>
 <result pre="Distress Syndrome and Death in Patients With Coronavirus Disease 2019" exact="Pneumonia" post="in Wuhan, China. JAMA Intern. Med.180 (7), 934. 10.1001/jamainternmed.2020.0994"/>
 <result pre="Identification of Nafamostat as a Potent Inhibitor of Middle East" exact="Respiratory" post="Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based"/>
 <result pre="of Nafamostat as a Potent Inhibitor of Middle East Respiratory" exact="Syndrome" post="Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell"/>
 <result pre="of SARS coronavirus to its receptor damages islets and causes" exact="acute" post="diabetes. Acta Diabetol.47 (3), 193â€&quot;199. 10.1007/s00592-009-0109-419333547 YaoX.YeF.ZhangM.CuiC.HuangB.NiuP.et al. (2020)."/>
 <result pre="of Optimized Dosing Design of Hydroxychloroquine for the Treatment of" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis.71"/>
 <result pre="Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis.71 (15),"/>
 <result pre="Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis.71 (15), 732â€&quot;739."/>
 <result pre="Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis.71 (15), 732â€&quot;739. 10.1093/cid/ciaa23732150618"/>
 <result pre="T. (2020). Guidelines for the diagnosis and treatment of coronavirus" exact="disease" post="2019 (COVID-19) in China. Glob. Heal. Med.2 (2), 66â€&quot;72."/>
 <result pre="M.ChopinM. (2019). The Pleiotropic Effects of the GM-CSF Rheostat on" exact="Myeloid" post="Cell Differentiation and Function: More Than a Numbers Game."/>
 <result pre="J. Biol. Sci.16 (10), 1718. 10.7150/ijbs.4512332226289 ZhouP.YangX.-L.WangX.-G.HuB.ZhangL.ZhangW.et al. (2020). A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
 <result pre="pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe" exact="pulmonary" post="syndrome patients of a new coronavirus. bioRxiv.2020.02.12.945576. 10.1101/2020.02.12.945576 ZieglerC."/>
 <result pre="GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary" exact="syndrome" post="patients of a new coronavirus. bioRxiv.2020.02.12.945576. 10.1101/2020.02.12.945576 ZieglerC. G."/>
</results>
